Together, these findings suggest that pharmacologic inhibition of NACC1 with NIC3 attenuates PNPLA3-148M–driven inflammation and fibrosis, and may represent a promising strategy for preventing or treating MASLD. This evidence concerns the gene NACC1 and metabolic dysfunction-associated steatotic liver disease.